Status:
TERMINATED
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
Lead Sponsor:
Santen Inc.
Collaborating Sponsors:
MacuSight, Inc.
Conditions:
Age-related Macular Degeneration
Choroidal Neovascularization
Eligibility:
All Genders
50+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal ne...
Eligibility Criteria
Inclusion
- Inclusion Criteria include, but are not limited to:
- Diagnosed with sub-foveal choroidal neovascularization secondary to age-related macular degeneration
- Visual acuity of 20/50 to 20/200 in study eye
- Exclusion Criteria:
- Any other ocular disease that could compromise vision in the study eye
- History of any prior treatment for choroidal neovascularization in the study eye
- Presence of other causes of choroidal neovascularization other than secondary to age-related macular degeneration
Exclusion
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00712491
Start Date
September 1 2008
End Date
March 1 2010
Last Update
January 10 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Retinal Consultants of Arizona
Phoenix, Arizona, United States, 85044